Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group by Buckstein, Rena et al.
ORIGINAL ARTICLE: CLINICAL
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a
clinical and pharmacodynamic phase II multicenter study of the NCIC
Clinical Trials Group
RENA BUCKSTEIN
1, JOHN KURUVILLA
2, NEIL CHUA
3, CHRISTINA LEE
1,
DAVID A. MACDONALD
4, ABDULWAHAB J. AL-TOURAH
5, ALISON H. FOO
6,
WENDY WALSH
6, S. PERCY IVY
7, MICHAEL CRUMP
8, & ELIZABETH A. EISENHAUER
6
1Sunnybrook Health Sciences Center, Toronto, ON, Canada,
2Department of Medical Oncology and Hematology, Princess
Margaret Hospital, University Health Network, Toronto, ON, Canada,
3Cross Cancer Institute, Edmonton, AB, Canada,
4QEII Health Sciences Centre, Halifax, NS, Canada,
5BC Cancer Center-Fraser Valley Center, Surrey, BC, Canada,
6NCIC
Clinical Trials Group, Kingston, ON, Canada,
7National Cancer Institute, Rockville, MD, USA, and
8Medical Oncology and
Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
(Received 4 November 2010; revised 13 January 2011; accepted 14 January 2011)
Abstract
There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted
a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg
given orally once daily in adult patients with relapsed or refractory DLBCL. Of 19 enrolled patients, 17 eligible patients were
evaluable for toxicity and 15 for response. No objective responses were seen and nine patients achieved stable disease
(median duration 3.4 months). As a result, the study was closed at the end of the ﬁrst stage. Grades 3–4 neutropenia and
thrombocytopenia were observed in 29% and 35%, respectively. There was no relationship between change in circulating
endothelial cell numbers (CECs) and bidimensional tumor burden over time. Despite some activity in solid tumors, sunitinib
showed no evidence of response in relapsed/refractory DLBCL and had greater than expected hematologic toxicity.
Keywords: Sunitinib, large cell lymphoma, angiogenesis, CEC, CEP, biomarker
Introduction
Despite the improved cure rates achieved by adding
rituximab to anthracycline-based chemotherapy in
aggressive-histology B-cell lymphomas [1–4], re-
lapsed or primary refractory diffuse large cell
lymphomas continue to pose major clinical chal-
lenges, with disappointing results. Selected patients
may be eligible for second-line therapy using high
dose chemotherapy (HDCT) and autologous stem
cell transplant (ASCT), but only 25–30% are cured
[5]. In the remaining patients, palliative chemother-
apy combined with corticosteroids offers temporary
relief in some cases, but survival is typically short [6].
Therefore, there is an urgent need to identify
alternative clinical approaches that either replace or
enhance chemotherapy, offering better disease con-
trol with less toxicity.
Sunitinib maleate (SUTENT; Pﬁzer Inc., New
York, NY), is an oral multi-targeted tyrosine kinase
inhibitor of vascular endothelial growth factor
(VEGF) receptors (VEGFR-1, -2, and -3) and
platelet derived-growth factor receptors (PDGFR-a
and -b) in addition to KIT, FLT3, RET, and CSF-1
[7,8]. This broad range of receptor inhibition may
confer both antiangiogenic effects and direct anti-
tumor effects, depending on the tumor subtype.
Sunitinib 50 mg given on the schedule of 4 weeks on/
2 weeks off provides progression-free and overall
survival beneﬁt in renal cell carcinoma (RCC) and
progression-free survival beneﬁt in imatinib-resistant
gastrointestinal stromal tumors (GISTs) [8–10].
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of large cell lymphomas [11–18], and the evidence
that VEGF and PDGF may promote lymphoma cell
growth in both a paracrine and an autocrine fashion
[19–21], the NCIC (NCIC) Clinical Trials Group
undertook a phase II study to evaluate the efﬁcacy of
sunitinib in patients with relapsed or refractory
diffuse or mediastinal (thymic) large B-cell lympho-
ma (DLBCL and PMBCL) or transformed B-cell
lymphomas. We chose a dose of 37.5 mg p.o. daily
with no planned breaks, since this had demonstrated
comparable beneﬁt in GIST without an increase in
toxicity [22], and the evidence from laboratory
studies suggested that antiangiogenic agents have
greater efﬁcacy when given continuously without
interruption [23,24].
Materials and methods
Patients
Adults aged 18 or older with relapsed or refractory
DLBCL, PMBCL, or transformed lymphomas were
eligible. Additional key inclusion criteria included at
least one and no more than two prior cytotoxic
chemotherapy regimens (one must have been
anthracycline-containing). Salvage chemotherapy
with HDCT/ASCT and up to one other chemother-
apy and non-chemotherapy regimen (e.g. radiation)
were permitted. Eligible patients must have been
able to stop selected CYP3A4 inhibitors/inducers
prior to starting sunitinib, have adequate cardiac
function, have measurable bidimensional disease,
and have an Eastern Cooperative Oncology Group
(ECOG) performance status of 0–1. Key exclusion
criteria were concurrent use of other antilymphoma
therapy, prior use of sunitinib, other antiangiogenic
agents, or multi-targeted receptor tyrosine kinase
(RTK) inhibitors, uncontrolled hypertension, symp-
tomatic cardio- or cerebrovascular disease, thera-
peutic anticoagulation, human immunodeﬁciency
virus (HIV), and brain metastases. In addition,
patients were excluded if they had a history of
cerebrovascular accident, pulmonary embolism, or
myocardial infarction within 12 months prior to
study enrollment.
The study was approved by the institutional review
boards of the participating NCIC Clinical Trials
Group institutions and was registered with clinical-
trials.gov. Written informed consent was obtained
from all patients before study participation.
Study design
This was a non-randomized, non-blinded multi-
center phase II trial of sunitinib in patients with
relapsed or refractory DLBCL or PMBCL con-
ducted by the NCIC Clinical Trials Group. Sunitinib
was supplied by the Cancer Therapy Evaluation
Program (CTEP) of the US National Cancer
Institute.
The primary endpoint of this study was objective
response. Response was deﬁned as per the report of
the international workshop to standardize response
criteria for non-Hodgkin lymphoma (NHL) [25].
The secondary endpoints included progression-free
survival, toxicity, and the evaluation of antiangio-
genic activity as determined by serial assessment of
the number of circulating endothelial cells (CECs),
apoptotic CECs (aCECs), and their precursors
(CEPs).
Treatment
Patients self-administered sunitinib 37.5 mg orally
once daily in 4-week cycles. Dose modiﬁcations were
made for toxicities graded according to the Cancer
Therapy Evaluation Program, National Cancer
Institute Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0. Up to two dose
reductions (25 mg then 12.5 mg) were permitted
for pre-speciﬁed toxicities. Grades 3–4 hematologic
and grade 3 non-hematologic adverse events (AEs)
generally required one dose reduction after resolu-
tion to  grade 2. Grade 4 non-hematologic AEs
generally led to study discontinuation. Grade 2
hypertension was treated with antihypertensive med-
ications until the blood pressure (BP) was controlled
to a mild hypertension range. The drug was held for
grade 3 hypertension until BP was controlled, then
resumed with one dose reduction. Grade 4 hyperten-
sion led to study discontinuation. Patients requiring
more than two dose reductions were removed from
the study. No dose re-escalations were permitted.
Patients who did not recover from toxic effects as
required within 2 weeks were removed from protocol
therapy.
Assessments
Patients were clinically assessed every 4 weeks.
Tumor imaging with computed tomography (CT)
scans and assessment of cardiac function by electro-
cardiography (ECG) and multi-gated acquisition
(MUGA) scan were performed at baseline and every
8 weeks while the patient remained on study.
Anatomic response assessments were performed
locally at each site based on the largest bidimensional
marker lesions identiﬁed at baseline. In the absence
of serious or unmanageable toxicity, patients with
complete response (CR), partial response (PR), or
stable disease (SD) continued on therapy until
834 R. Buckstein et al.disease progression or for a maximum of 12 cycles (1
year). Earlier discontinuation of therapy was permis-
sible if continued treatment was no longer consid-
ered in the patient’s best interest. In addition,
patients who progressed (treatment failure) went off
study at the time progression was documented
clinically and/or radiographically. At the conclusion
of the trial, a central review of X-rays and/or scans
was to be carried out for any investigator-claimed
responses.
CECs and CEPs were measured in three Ontario
centers at baseline, day 1 of cycles 2 and 3, every 3
months thereafter, and at study discontinuation.
Flow cytometric analysis was performed in one
central location using previously published methods
[26].
Statistical methods
A Simon two-stage design was used [27]. A response
rate of 5% was not considered promising, while a
20% response rate was worthy of further study. If no
responses were seen in the ﬁrst cohort of 15 evaluable
patients, no further accrual would take place. If one
or more responses were seen in group 1, then an
additional 10 patients would be accrued. The study
would be considered positive and sunitinib of interest
in DLBCL and its variants if at least three responses
were seen in the group of 25 patients (alpha: 0.12;
beta: 0.89). All time-to-event data were described
using the Kaplan–Meier method. Blood levels of
CECs, aCECs, and CEPs (cells/mL) were plotted as
percent change from baseline in comparison with the
sum of bidimensional measurements of marker
lymph nodes over time.
Results
Patient characteristics
A total of 19 patients were enrolled between
February 2007 and September 2008 at seven
Canadian sites. Two patients were deemed ineligible
(one no histological diagnosis, one pulmonary
embolism512 months prior to entry). Seventeen
patients were evaluable for toxicity and 15 were
evaluable for response. Baseline patient character-
istics are outlined in Table I. The median age was 65
and median time from lymphoma diagnosis was 20.3
months (range 5.8–132 months). Fourteen patients
had a diagnosis of DLBCL, 10 had immediately
preceding chemosensitive disease (complete or par-
tial response to last treatment), and ﬁve had relapsed
post-HDCT and -ASCT. The majority (11 patients)
had an elevated serum lactate dehydrogenase (LDH)
at the time of study enrollment.
Treatment delivery
The median number of cycles of sunitinib received
was 2 (1–5), with only ﬁve patients remaining on
drug for three or more cycles. Only six of 17 patients
received  90% of the planned dose intensity, with 14
patients missing doses and ﬁve undergoing dose
reductions necessitated by toxicities (Tables II and
III).
Safety
The most commonly reported non-hematologic
treatment-related AEs thought to be at least possibly
related to sunitinib were: fatigue (59%), anorexia
(47%), nausea (47%), diarrhea (35%), vomiting
(29%), mucositis, clinical exam and functional/
symptomatic (24% and 18%, respectively), heart-
burn (24%), and hypertension (24%), with most of
these events of mild or moderate intensity (grades 1
Table I. Baseline characteristics.
Characteristic No.
Median age, years (range) 65 (34–81)
Gender
Female 7
Male 10
Performance status (ECOG)
05
11 2
Prior chemotherapy
1 prior chemotherapy regimen 7
2 prior chemotherapy regimens 10
High dose/ASCT 5
Rituximab 16
Prior radiotherapy 8
Best response to last chemotherapy
Unknown 1
Complete response 7
Partial response 3
Stable disease 3
Progressive disease 2
Inevaluable 1
Number of sites of disease
15
23
33
4 (or more) 6
Histology
DLBCL 14
PMBCL 1
Transformed diffuse large B-cell 2
Baseline LDH
 ULN 6
41–2.5 6 ULN 4
42.5–5 6 ULN 3
45 6 ULN 4
ECOG, Eastern Cooperative Oncology Group; ASCT, autologous
stem cell transplant; DLBCL, diffuse large B-cell lymphoma;
PMBCL, primary mediastinal B-cell lymphoma; LDH, lactate
dehydrogenase; ULN, upper limit of normal.
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asymptomatic reduction in left ventricular (LV)
systolic function, two developed grade 1 pleural
effusion, and four developed elevated thyroid stimu-
lating hormone (TSH) on treatment, although only
two required thyroid replacement. One patient had a
grade 4 pericardial effusion develop on study, but
this was deemed to be related to progressive
lymphoma, not to sunitinib. Neutropenia and
thrombocytopenia were grade 3 or more in ﬁve and
six patients, respectively (Table III), and were the
most common reason for dose omission or reduc-
tion. Six patients (35%) discontinued treatment due
to AEs, four of which were hematologic, and eight
patients discontinued therapy due to disease progres-
sion. There were no treatment-related deaths.
Efﬁcacy
Of 17 eligible patients, 15 were evaluable for
response. One patient received only two doses of
drug, and one patient did not have restaging scans.
Of those evaluable, no patient experienced a clinical
response to sunitinib after central radiology review.
As a result, the study was closed to accrual according
to the protocol. Nine patients (53%) achieved stable
disease as best response (median duration 3.4
months; range: 1.4–8.7 months), and six (35%) had
primary progressive disease. Overall progression-free
survival (PFS) (Figure 1) was 2.2 months (95%
conﬁdence interval [CI] 1.41–3.48). All patients are
currently off study, eight due to disease progression,
one due to symptomatic progression, and six due to
toxicity, and two withdrew consent.
Analysis of biomarkers
CECs, aCECs, and CEPs were assessed at baseline
in 10 patients and in two or more serial measure-
ments in seven patients (six of whom had restaging
CT scans for comparison). The median baseline
CEC count was 2.9 cells/mL (range 1.13–7.03 cells/
mL), of which 86% (range 30–99%) were viable. CEP
levels were too low to be serially followed. There was
no discernible relationship between the change in
absolute or apoptotic CECs over time and clinical
response or change in bidimensional measurements
(Figure 2). Sixty-seven percent of the patients with
stable disease had a normal LDH at baseline
compared with 0% in patients with primary progres-
sive disease.
Discussion
As in solid tumors, neo-angiogenesis may contribute
to the pathogenesis and poor prognosis in many
aggressive-histology lymphomas. The detection of
VEGF A, B, and C isoforms and their receptors on
many large cell lymphoma samples suggests that the
VEGF pathway is critically important, and may
contribute to disease progression in both an auto-
crine and a paracrine fashion [12,17,18,28,29].
Table II. Most common adverse events according to grade.
Adverse event
Grades
1–2
Grades
3–4 Total
No. % No. % No. %
Hypertension 1 6 3 18 4 24
Fatigue 7 41 3 18 10 59
Anorexia 6 35 2 12 8 47
Dehydration 3 18 – – 3 18
Diarrhea 4 24 2 12 6 35
Heartburn 4 24 – – 4 24
Mucositis (clinical exam) 4 24 – – 4 24
Mucositis (functional/
symptomatic)
31 8– – 3 1 8
Nausea 8 47 – – 8 47
Taste alteration 3 18 – – 3 18
Vomiting 5 29 – – 5 29
Pain oral cavity 3 18 – – 3 18
Table III. Hematological adverse events.
Adverse event
Grade
01234
Granulocytes 4265–
Hemoglobin 18521
Lymphopenia 32642
Platelets 37133
Leukocytes 4247–
Figure 1. Overall survival.
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mab has been evaluated in relapsed DLBCL,
resulting in one partial response and eight patients
with stable disease as best response, out of 30
evaluable patients; 6-month PFS, the primary
study endpoint, was 15% (95% CI 5–26%) [30].
Figure 2. Percent change (from baseline) in bidimensional measurements compared with percent change in circulating endothelial cells
(panel A), and apoptotic circulating endothelial cells (panel B) over time measured in days. CECs, circulating endothelial cells.
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ing CHOP-R (cyclophosphamide, doxorubicin, vin-
cristine, prednisone, and rituximab) with CHOP-R
þ bevacizumab was recently discontinued due to
excess cardiac morbidity, and the clinical beneﬁts of
adding an antiangiogenic agent to standard treatment
are still unknown.
The evaluation of agents targeting VEGF signal-
ing in NHL, notably DLBCL, is of interest.
Sunitinib (SU11248) was a logical agent to study,
since it is an orally bioavailable inhibitor affecting
RTKs involved in tumor proliferation and angio-
genesis, including VEGFR-1, -2, and -3, and
PDGFR-a and -b.
Figure 2. (Continued).
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37.5 mg p.o. daily did not produce objective radi-
ologic responses in patients with relapsed or refrac-
tory DLBCL or transformed lymphoma, with short-
lived stable disease as the best achievable response in
53% of patients. This contrasts with objective
response rates of 25.5–36.5% in metastatic RCC
[10], 23% in bevacizumab-refractory metastatic
RCC [31], 16% in advanced pancreatic neuroendo-
crine tumors [32], and 11% in advanced non-small
cell lung cancer [33]. The lack of response in
lymphoma is congruent with the sunitininb experi-
ence in heavily pretreated chronic lymphocytic
leukemia (CLL) [34].
These negative results may be explained by a
number of factors. First, diffuse large cell lymphomas
are rapidly proliferating tumors that may not be
suited to treatment with cytostatic agents used as
monotherapy. The median time on drug (2 months)
may have been too short to demonstrate any efﬁcacy
in many patients whose baseline elevated LDH
suggested highly mitotic tumors. Second, the dose
of sunitinib chosen for testing in this patient
population, 37.5 mg daily, may have been too low,
despite the continuous schedule used. Most clinical
trials of sunitinib reporting signiﬁcant objective
response rates have used 50 mg daily for 4 out of 6
weeks. We selected the lower dose to permit
continuous administration and to avoid the rebound
increase in markers of angiogenesis observed after
angiogenesis inhibitors are stopped [35–37]. How-
ever, despite a lower daily dose, we encountered
unexpected excessive myelosuppression induced by
sunitinib, which compromised the ability to admin-
ister even the reduced dosage intended in this study
on schedule, and accounted for many of the AEs that
led to study treatment discontinuation. This may be
because 37.5 mg daily is a comparable if not slightly
higher total dose over a 6-week period than the total
dose of the 50 mg syncopated 6-week schedule. Or
perhaps, in this patient population who have been
previously treated with multiagent chemotherapy
(including alkylators and anthracyclines) and, fre-
quently, ASCT, an interrupted schedule (as has been
evaluated in patients with solid tumors) may have
allowed greater drug delivery. Our hematologic
adverse event experience is not dissimilar to that
reported in heavily pretreated patients with CLL
given sunitinib 37.5 mg p.o. daily [34]. In that trial,
16 of 18 (89%) patients experienced grade 3 or
higher adverse events to sunitinib, with 56%  grade
3 thrombocytopenia and 27%  grade 3 neutropenia.
These data, together with those from our trial,
suggest that patients with lymphoid cancers may
experience greater myelosuppression because of the
presence of extensive marrow involvement, as might
be expected in patients with CLL, or due to the
nature of their prior therapy, such as exposure to
purine analogs or following ASCT.
Clinical trials for traditional cytotoxic drugs are
often designed to show an improvement in the
objective response rate. Many of the newer anti-
cancer agents, including those targeting angiogen-
esis, may have a primarily cytostatic rather than a
cytotoxic effect, and may delay progression and/or
death while having little effect on tumor size. In the
absence of randomized trials wherein time-to-event
endpoints such as time to tumor progression can be
reliably compared with a control group [8,10],
surrogate biomarkers are needed to help validate
the mechanistic hypotheses of action, identify re-
sponsive patients and optimal biologic doses, and
predict the outcomes of regimens that include anti-
VEGF agents.
CECs and their progenitors (CEPs) are rarely
found in the blood of healthy subjects, but may be
elevated in patients with neoplastic disease and
correlate with angiogenesis [38]. Preclinically,
CECs appear to correlate with tumor volumes in
SCID (severe combined immunodeﬁciency) mice
bearing human lymphoma [39]. Increased
CD133þCD34þVEGFR-2þ endothelial precursor
cells (EPCs) are detectable in the peripheral blood of
patients with aggressive lymphomas and decrease in
number following complete response to chemother-
apy [40]. Additionally, bevacizumab reduced the
frequency of viable CECs and CEPs in patients with
rectal cancer [41], and in a previous study in patients
with relapsed aggressive lymphomas, CECs and
CEPs declined during metronomic low-dose cyclo-
phosphamide and high dose celecoxib [42].
The lack of correlation between tumor response as
measured by bidimensional measurements and
changes in CECs contrasts with the observations in
patients with RCC treated with sunitinib on a 50 mg
daily for 4 weeks, with 2 weeks off, schedule [43].
While on sunitinib, opposite kinetics of two circulat-
ing CD34
bright cell populations, hematopoietic pro-
genitor cells (HPCs) and small CECs, were
observed, with the HPCs decreasing and the CECs
increasing but normalizing to pretreatment values
during the 2-week drug-free period. This suggested
that sunitinib was directly targeting the immature
tumor vessels. In another study, sunitinib was
reported to cause a greater increase in CECs in
patients with GIST, and this increase was associated
with clinical beneﬁts compared with patients with
progressive disease [44].
The problematic reproducibility and validity of
measuring low frequency CECs by ﬂow cytometry is
known, but our negative ﬁndings may simply reﬂect
the limited power of this analysis due to serial
Sunitinib in diffuse large B-cell lymphoma 839monitoring of a small number of patients (n¼8) for a
median of two cycles.
Finally, cytostatic agents probably work best when
used in combination with chemotherapy. Despite
this, it would be unrealistic to pursue more drug
development with sunitinib in combination with
chemotherapy in the absence of single-agent activity
(or tolerability). The absence of any objective
responses negatively predicts for eventual regulatory
approval of a given therapeutic agent in solid tumors.
There is no reason to suppose that in lymphomas,
which are often more sensitive to a speciﬁc che-
motherapeutic agent than are solid tumors, this
observation with respect to targeted agents would
not also hold true. Indeed, all recently approved new
agents in lymphoma demonstrated objective re-
sponses when given as single agents [45].
Conclusion
Sunitinib administered 37.5 mg p.o. daily was
inactive in patients with relapsed or refractory
DLBCLs and resulted in greater hematological and
other toxicities compared to the experience in
populations with solid tumors. No convincing
pharmacodynamic evidence of antiangiogenic activ-
ity was demonstrable by CEC and CEP biomarker
analysis, with the qualiﬁcation that limited serial
sampling was possible.
Inour opinion, this study illustrates the challenge of
studying novel targeted therapies including antiangio-
genesis agents in rapidly proliferating lymphomas.
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